"Pentostatin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A potent inhibitor of ADENOSINE DEAMINASE. The drug induces APOPTOSIS of LYMPHOCYTES, and is used in the treatment of many lymphoproliferative malignancies, particularly HAIRY CELL LEUKEMIA. It is also synergistic with some other antineoplastic agents and has immunosuppressive activity.
| Descriptor ID |
D015649
|
| MeSH Number(s) |
D03.383.742.680.350.200.700 D13.570.230.677 D13.570.685.350.200.700
|
| Concept/Terms |
Pentostatin- Pentostatin
- Deoxycoformycin
- Co-Vidarabine
- 2'-Deoxycoformycin
- 2' Deoxycoformycin
|
Below are MeSH descriptors whose meaning is more general than "Pentostatin".
Below are MeSH descriptors whose meaning is more specific than "Pentostatin".
This graph shows the total number of publications written about "Pentostatin" by people in this website by year, and whether "Pentostatin" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 1 | 0 | 1 |
| 1997 | 0 | 1 | 1 |
| 2000 | 1 | 0 | 1 |
| 2002 | 1 | 0 | 1 |
| 2008 | 1 | 0 | 1 |
| 2011 | 0 | 1 | 1 |
| 2013 | 1 | 0 | 1 |
| 2015 | 0 | 1 | 1 |
| 2020 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Pentostatin" by people in Profiles.
-
Incorporation of extracorporeal photopheresis into a reduced intensity conditioning regimen in myelodysplastic syndrome and aggressive lymphoma: results from ECOG 1402 and 1902. Transfusion. 2020 08; 60(8):1867-1872.
-
High-Dose Sirolimus and Immune-Selective Pentostatin plus Cyclophosphamide Conditioning Yields Stable Mixed Chimerism and Insufficient Graft-versus-Tumor Responses. Clin Cancer Res. 2015 Oct 01; 21(19):4312-20.
-
The hematopoietic cell transplantation specific comorbidity index and survival after extracorporeal photopheresis, pentostatin, and reduced dose total body irradiation conditioning prior to allogeneic stem cell transplantation. Leuk Res. 2013 Sep; 37(9):1052-6.
-
Fifty years of hairy cell leukemia treatments. Leuk Lymphoma. 2011 Jun; 52 Suppl 2:3-5.
-
Hairy cell leukemia: treatment successes in the past 25 years. J Clin Oncol. 2008 Jun 01; 26(16):2607-9.
-
Purine nucleoside analogues and combination therapies in B-cell chronic lymphocytic leukemia: dawn of a new era. Leuk Res. 2004 May; 28(5):429-42.
-
Pentostatin pharmacokinetics and dosing recommendations in patients with mild renal impairment. Cancer Chemother Pharmacol. 2002 Aug; 50(2):121-6.
-
Long-term follow-up of remission duration, mortality, and second malignancies in hairy cell leukemia patients treated with pentostatin. Blood. 2000 Nov 01; 96(9):2981-6.
-
Concentrations of adenosine and its metabolites in the rat retina/choroid during reperfusion after ischemia. Curr Eye Res. 1997 Sep; 16(9):875-85.
-
Randomized comparison of pentostatin versus interferon alfa-2a in previously untreated patients with hairy cell leukemia: an intergroup study. J Clin Oncol. 1995 Apr; 13(4):974-82.